Nurix Shows Promising CSU Data for Bexobrutideg
BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...
CSU
Advertisement
CuraTeQ Reports Positive Phase 3 Results for BP11 Biosimilar
Hyderabad, India, April 7, 2026 Phase 3 Trial Confirms Biosimilar Equivalence In a significant milestone for biosimilar drug development,...
Valneva Reports Strong Phase 2 Data for VLA15 Vaccine
SAINT-HERBLAIN, FRANCE — November 26, 2025. Valneva has announced positive final Phase 2 results for its Lyme disease vaccine...
EU Approves Dupixent as First Targeted CSU Therapy
TARRYTOWN, N.Y. & PARIS — November 25, 2025. The European Commission has granted landmark approval for Dupixent® (dupilumab) as...
Novartis wins FDA approval for first oral BTKi in chronic urticaria
EAST HANOVER, N.J., Sept. 30, 2025 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
